Report Subject - Market Access - Page 1

Learn More Patient Journey Mapping for Market Access

Which market access teams will be first to unlock the power of patient journey mapping? There's no doubt that market access has evolved significantly in recent years, but there is so much more to be done. What some...

Compare
Learn More Benchmarking Pharma’s Digital Marketing Capabilities

Pharma is behind the curve in digital marketing. What does the industry need to do to fully release the power of digital communications? Driven by customer demand, digital marketing has grown in importance and is now...

Compare
Learn More Biosimilars in Emerging Markets (2018)

Biosimilars: Evaluating opportunities and risks in emerging markets Are you seeking new opportunities for biosimilars? The potential in emerging markets remains attractive, however the high-profile BRIC countries - and...

Compare
Learn More Payer Engagement: Benchmarking team structure and activity

Benchmark your payer engagement team's performance against the industry's best! Winning payer support to secure reimbursement and optimum pricing is a battle payer engagement teams' face daily. But in the face of ever...

Compare
Learn More Benchmarking Market Access Strategies for High-Cost Drugs and Biologics

How to secure commercial advantage in the speciality drugs arena What is the secret of commercial success for high cost specialty drugs? More specifically, what do the companies that overcome affordability and value...

Compare
Learn More Succeeding with value based contracts

Get up-to-speed on value-based contracting before your competitors take the lead Hailed by some as the answer to the drug cost crisis, value-based contracting (VBC) is currently dominating the agenda in pharma...

Compare
Learn More Trends in Biomarkers and CDx

Technical advances are ushering in a new era for companion diagnostics. What does Pharma need know? The introduction of liquid biopsies and advances in next generation sequencing are just the latest developments driving...

Compare
Learn More Charting MSL Activity & Performance 2018

Benchmark your MSL practice and performance against the industry's best! The critical Medical Science Liaison (MSL) function is being stretched as the need to meet the demands of KOLs, HCPs, patients and payers grows...

Compare
Learn More HTA in Europe: Key Success Factors for Positive HTA Recommendations

Is there a magic formula for achieving HTA approvals in Europe? Securing a HTA approval in Europe makes sound commercial sense but it's proving easier said than done. Negative or restrictive HTA recommendations are on...

Compare
Learn More Paying for Digital Health: Payer Insights

Payers love digital technologies that reduce health costs and deliver patient benefit–but who should pick up the tab? Digital technology is revolutionising healthcare from advanced electronic medical records and...

Compare
Learn More Pricing and Reimbursement in Neurology

When first line treatments for neurological diseases such as Parkinson's Disease (PD) and Multiple Sclerosis (MS) have been around for years, it's understandable that when something new is approved, people want to try it...

Compare
Learn More Pricing and Reimbursement in Oncology: Payer views

As payer and stakeholder anger mounts, when will the oncology drug price bubble burst? Global cancer drug prices have increased by 10% every year between 1995 and 2013. That level of price inflation is not sustainable...

Compare
Learn More Value-Added Services in Oncology: What motivates payers?

Are your value-added services (VAS) in oncology meeting the needs of payers as well as patients and physicians? Payers are increasingly taking interest in beyond-the-pill services that improve patient adherence,...

Compare
Learn More The Importance of Real World Evidence in Orphan Drugs

Proof of value is an imperative for orphan drug manufacturers: it's the only route to improving patient access and overcoming unmet therapeutic needs for rare conditions. Progress has been made with real world data (RWD)...

Compare
Learn More Market Access Team Structure and Function: Industry Survey 2017

This report gives a unique insight into how US and European market access teams are organised and how they are focusing their time on a day-to-day basis. Market Access Team Structure and Function: Industry Survey 2017...

Compare
Learn More Innovative drugs: Mapping the pricing, reimbursement and HTA landscape

Widespread patient access to innovative new products is being frustrated in non-US markets by Health Technology Assessments (HTA). Between January 2016 and June 2017, 58 innovative medicines were approved and launched in...

Compare

Browse by